Loading...
•
Mar 31, 2021
Replimune Q4 2021 Earnings Report
Reported financial results for the fiscal fourth quarter and year ended March 31, 2021, and provided a business update.
Key Takeaways
Replimune reported its fiscal fourth-quarter and year-end 2021 financial results. The company is advancing its clinical programs and expects data updates in June. They ended the year with approximately $476 million in cash, which is expected to fund operations into the second half of 2024.
Added complete response as an independent primary endpoint in registration-directed CERPASS study in CSCC.
Held Type B meeting with FDA to discuss the IGNYTE study in anti-PD1 failed melanoma.
Dosed first patient with RP1 in the anti-PD1 failed NSCLC lung cancer cohort of the IGNYTE study.
Ended fiscal year 2021 with approximately $476 million in Cash; Capitalized into second half of 2024.
Replimune
Replimune
Forward Guidance
Replimune believes that existing cash and cash equivalents and short-term investments will fund operating expenses and capital expenditure requirements into the second half of 2024.